PeterHaraldLangsjoenMDFACC

PubMed

• 1 citations
  Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations.
  Beatrice A Golomb, Jun Hee Han, Peter H Langsjoen, Eero Dinkeloo, Alice E Zemljic-Harpf> ;Journal of Clinical Medicine. 2023 Jul 13
• 3 citations
  Platelet mitochondrial respiration and coenzyme Q10 could be used as new diagnostic strategy for mitochondrial dysfunction in rheumatoid diseases.
  Anna Gvozdjáková, Zuzana Sumbalová, Jarmila Kucharská, Monika Szamosová, Lubica Čápová, Zuzana Rausová, O Vancova, Viliam Mojto, Peter Langsjoen, Patrik Palacka> ;Plos One. 2021 Jan 1
• 8 citations
  The new European guidelines for prevention of cardiovascular disease are misleading
  Uffe Ravnskov, Abdullah A Alabdulgader, Michel de Lorgeril, David M. Diamond, Rokuro Hama, Tomohito Hamazaki, Björn Hammarskjöld, Zoë Harcombe, Malcolm Kendrick, Peter...> ;Expert Review of Clinical Pharmacology. 2020 Dec 1
• 2 citations
  Response letter to 'does high LDL-cholesterol cause cardiovascular disease?'
  Uffe Ravnskov, Michel de Lorgeril, David M. Diamond, Rokuro Hama, Tomohito Hamazaki, Björn Hammarskjöld, Niamh Hynes, Malcolm Kendrick, Peter H Langsjoen, Luca Mascite...> ;Expert Review of Clinical Pharmacology. 2019 Jan 16
• 7 citations
  Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q10.
  Peter H. Langsjoen, Jens Langsjoen, Alena M. Langsjoen, Franklin Rosenfeldt> ;The Permanente Journal. 2019 Jan 1
• 72 citations
  LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
  Uffe Ravnskov, Michel de Lorgeril, David M. Diamond, Rokuro Hama, Tomohito Hamazaki, Björn Hammarskjöld, Niamh Hynes, Malcolm Kendrick, Peter H Langsjoen, Luca Mascite...> ;Expert Review of Clinical Pharmacology. 2018 Oct 11
• 172 citations
  Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review
  Uffe Ravnskov, David M. Diamond, Rokura Hama, Tomohito Hamazaki, Björn Hammarskjöld, Niamh Hynes, Malcolm Kendrick, Peter H Langsjoen, Aseem Malhotra, Luca Mascitelli,...> ;BMJ Open. 2016 Jun 1
• 15 citations
  Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes.
  Harumi Okuyama, Peter H. Langsjoen, Naoki Ohara, Yoko Hashimoto, Tomohito Hamazaki, Satoshi Yoshida, Tetsuyuki Kobayashi, Alena M. Langsjoen> ;Pharmacology. 2016 Jan 1
• 69 citations
  Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms
  Harumi Okuyama, Peter H Langsjoen, Tomohito Hamazaki, Yoichi Ogushi, Rokuro Hama, Tetsuyuki Kobayashi, Hajime Uchino> ;Expert Review of Clinical Pharmacology. 2015 Feb 19
• 42 citations
  Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone
  Peter H. Langsjoen, Alena M. Langsjoen> ;Clinical Pharmacology in Drug Development. 2014 Jan 1
• 43 citations
  Supplemental ubiquinol in patients with advanced congestive heart failure
  Peter H. Langsjoen, Alena M. Langsjoen> ;Biofactors. 2008 Jan 1
• 2 citations
  Statin contraindicated in heart failure.
  Eddie Vos, Luca Mascitelli, Peter H Langsjoen> ;Angiology. 2008 May 27
• 114 citations
  Coenzyme Q10 and statins: biochemical and clinical implications.
  Gian Paolo Littarru, Peter H. Langsjoen> ;Mitochondrion. 2007 Jun 1
• 47 citations
  Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation
  Peter H. Langsjoen, Jens Langsjoen, Alena M. Langsjoen, Lindsay A. Lucas> ;Biofactors. 2005 Jan 1
• 68 citations
  Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction
  Marc A. Silver, Peter H. Langsjoen, Szabolcs Szabo, Harish Patil, Allan Zelinger> ;The American Journal of Cardiology. 2004 Nov 15
• 69 citations
  The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications.
  Peter H. Langsjoen, Alena M. Langsjoen> ;Biofactors. 2003 Jan 1
• 11 citations
  Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol.
  Marc A. Silver, Peter H. Langsjoen, Szabolcs Szabo, Harish Patil, Allan Zelinger> ;Biofactors. 2003 Jan 1
• 24 citations
  Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure.
  Peter H Langsjoen> ;Journal of the American College of Cardiology. 2000 Mar 1
• 88 citations
  Overview of the use of CoQ10 in cardiovascular disease.
  Peter H. Langsjoen, Alena M. Langsjoen> ;Biofactors. 1999 Jan 1
• 37 citations
  Treatment of hypertrophic cardiomyopathy with coenzyme Q10
  Peter H. Langsjoen, Alena M. Langsjoen, Richard A. Willis, Karl Folkers> ;Molecular Aspects of Medicine. 1997 Jan 1
• 60 citations
  Treatment of essential hypertension with coenzyme Q10.
  Peter H. Langsjoen, Richard A. Willis, Karl Folkers> ;Molecular Aspects of Medicine. 1994 Jan 1
• 51 citations
  Usefulness of Coenzyme Q10 in clinical cardiology: A long-term study
  H. Langsjoen, Peter H. Langsjoen, Richard A. Willis, Karl Folkers> ;Molecular Aspects of Medicine. 1994 Jan 1
• 21 citations
  Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment.
  P. H. Langsjoen, K. Folkers> ;The Clinical Investigator. 1993 Jan 1
• 16 citations
  Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant.
  Karl Folkers, Peter H. Langsjoen, Per H. Langsjoen> ;Biochemical and Biophysical Research Communications. 1992 Jan 15
• 18 citations
  Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex.
  Karl Folkers, Takashi Hanioka, Li-Jun Xia, Judson T. Mcree, Peter H. Langsjoen> ;Biochemical and Biophysical Research Communications. 1991 Apr 30
• Join now to see all

Journal Articles

• Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms.  
  Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H., Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99., 3/8/2015
• Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone.  
  1. Langsjoen, P.H. and Langsjoen, A.M., Clinical Pharmacology in Drug Development, 2014 (Jan/Feb);3(1):13-17., 2/2014
• Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone  
  Langsjoen, P.H. and Langsjoen, A.M., Clinical Pharmacology in Drug Development, 1/1/2014
• Coenzyme Q10 and statins: biochemical and clinical implications.  
  Littarru G.P., Langsjoen P., Mitochondrion, 2007
• Role of concomitant coenzyme Q10 with statins for patients with hyperlipidemia  
  Langsjoen P.H., Littarru. g.P., Silver, M.A., Current Topics in Nutriceutical Research, 1/1/2005
• The clinical use of HMg CoA-reductase inhibitors and the associated depletion of coenzyme Q10 A review of animal and human publications  
  Langsjoen P.H, Langsjoen, A.M., BioFactors, 1/1/2003
• "Comment"  
  Langsjoen P.H., J Am Coll Cardiol, 3/1/2000
• Review of Coenzyme Q10 in Cardiovascular Disease with Emphasis on Heart Failure and Ischemia Reperfusion  
  Langsjoen P.H., Langsjoen A.M., Asia Pacific Heart J, 1/1/1998
• Lovastatin decreases coenzyme Q levels in humans  
  Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H, Proc Natl Acad Sci USA, 11/1/1990
• Biomedical and Clinical Aspects of Coenzyme Q  
  Langsjoen P.H., Langsjoen P.H., Morishita M., Muratzu K., Lyson K., Folkers K., 1/1/1986
• Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10  
  Langsjoen PH, Vadhanavikit S, Folkers K, Proc Natl Acad Sci U S A, 6/1/1985
• Join now to see all

Books/Book Chapters

• Anti-Aging Medical Therapeutics 
  Chapter: The Aging Heart: Reversal of Diastolic Dysfunction Through the Use of Oral CoQ10 in the Elderly. 
  Page 113 - 120Langsjoen P.H., Langsjoen A., Willis A, Folkers, K.Editors: R.M.Klatz and R. goldman.Health Quest Publications1997
• Biomedical and Clinical Aspects of Coenzyme Q 
  Chapter: Treatment of patients with human immunodeficiency virus infection with coenzyme Q10. 
  Page 409 - 415Langsjoen P.H., Langsjoen P.H., Folkers K., Richardson P.Editors: Folkers K., Littarru g.P., and Yamagami, T..1991

Abstracts/Posters

• Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone.
  Langsjoen, P.H. and Langsjoen, A.M., Clinical Pharmacology in Drug Development, 1/1/2014
• Statin contraindicated in heart failure.
  Vos E, Mascitelli L, Langsjoen PH, Angiology, 10/1/2008
• Supplemental ubiquinol in patients with advanced congestive heart failure.
  Langsjoen PH, Langsjoen AM, Biofactors, East Texas Medical Center and Trinity Mother Francis Hospital, TX, 1/1/2008
• Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation.
  Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA, BioFactors, East Texas Medical Center and Trinity Mother Francis Hospital, Tyler, TX, 1/1/2005
• Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction.
  Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A, Am J Cardiol, Heart Failure Institute, Department of Medicine, Advocate Christ Medical Center, University of Illin, 11/15/2004
• Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol.
  Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A, Biofactors, Heart Failure Institute, Division of Cardiology, Department of Medicine, Advocate Christ Medical Cen, 1/1/2003
• The clinical use of HMg CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications.
  Langsjoen PH, Langsjoen AM, BioFactors, East Texas Medical Center and Trinity Mother Francis Health System, Tyler, TX, 1/1/2003
• Overview of the use of CoQ10 in cardiovascular disease.
  Langsjoen PH, Langsjoen AM, BioFactors, 1/1/1999
• Review of Coenzyme Q10 in Cardiovascular Disease with Emphasis on Heart Failure and Ischemia Reperfusion.
  Langsjoen P.H., Langsjoen A.M., Asia Pacific Heart J, 1/1/1998
• Treatment of hypertrophic cardiomyopathy with coenzyme Q10.
  Langsjoen PH, Langsjoen A, Willis R, Folkers K, Mol Aspects Med, Langsjoen Clinic, Tyler, TX, 1/1/1997
• Usefulness of coenzyme Q10 in clinical cardiology: a long-term study.
  Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K, Mol Aspects Med, University of Texas Medical Branch, galveston, TX, 1/1/1994
• Treatment of essential hypertension with coenzyme Q10.
  Langsjoen P, Langsjoen P, Willis R, Folkers K, Mol Aspects Med, Institute for Biomedical Research, University of Texas at Austin, 1/1/1994
• Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment.
  Langsjoen PH, Langsjoen PH, Folkers K, Clin Investig, 1/1/1993
• Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant.
  Folkers K, Langsjoen P, Langsjoen PH, Biochem Biophys Res Commun, Institute for Biomedical Research, University of Texas, Austin, 1/1/1992
• Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex.
  Folkers K, Hanioka T, Xia LJ, McRee JT Jr, Langsjoen P, Biochem Biophys Res Commun, Institute for Biomedical Research, University of Texas, Austin, 1/1/1991
• Treatment of patients with human immunodeficiency virus infection with coenzyme Q10.
  Langsjoen P.H., Langsjoen P.H., Folkers K., Richardson P., Biomedical and Clinical Aspects of Coenzyme Q, 1/1/1991
• Lovastatin decreases coenzyme Q levels in humans.
  Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H, Proc Natl Acad Sci U S A, University of Texas, Austin, 1/1/1990
• Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy.
  Langsjoen PH, Langsjoen PH, Folkers K, Am J Cardiol, Scott and White Clinic, Temple, TX, 1/1/1990
• A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10.
  Langsjoen PH, Langsjoen PH, Folkers K, Int J Tissue React, Department of Medicine, Scott & White Clinic, Temple, TX, 1/1/1990
• Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy.
  Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P, Int J Tissue React, Department of Medicine, Scott and White Clinic, Temple, TX, 1/1/1990
• Effective and safe therapy with coenzyme Q10 for cardiomyopathy.
  Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P, Klin Wochenschr, Department of Medicine, Scott and White Clinic, Temple, TX, 1/1/1988
• Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment.
  Folkers K, Langsjoen P, Nara Y, Muratsu K, Komorowski J, Richardson PC, Smith TH, Biochem Biophys Res Commun, Institute for Biomedical Research, University of Texas, Austin, 1/1/1988
• The long-term value of Coenzyme Q10 in patients with cardiomyopathy.
  Langsjoen P.H., Langsjoen P.H., Morishita M., Muratzu K., Lyson K., Folkers K., Biomedical and Clinical Aspects of Coenzyme Q, 1/1/1986
• Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10.
  Langsjoen PH, Vadhanavikit S, Folkers K, Proc Natl Acad Sci U S A, 6/1/1985
• Coenzyme Q10 and statins: biochemical and clinical implications.
  Littarru GP, Langsjoen P, Institute of Biochemistry, Polytechnic University of the Marche, Via Ranieri, Ancona, Italy
• Join now to see all

Other

• Alleviating Congestive Heart Failure with Coenzyme Q10. 
  Langsjoen, P.H., Life Extension Magazine
  2/1/2008